245 results about "Diagnoses diseases" patented technology

The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.

Arrays containing a transcriptome of a diseased tissue and methods of using the arrays for diagnosis, prognosis, screening, and identification of disease are provided herein. The transcriptome arrays from diseased tissue are useful for diagnosis of a disease by analysis of the genetic profile of a tissue sample specific to a disease state. The genetic profiles are then correlated with data on the effectiveness of specific therapeutic agents. Correlating expression profiles to the effectiveness of therapeutic agents provides a way to screen and select further patients predicted to respond to those therapeutic agents, thereby minimizing needless exposure to ineffective therapy.

The present invention generally relates to the field of intravascular medical devices, and more specifically to the field of balloon catheters and other similar diagnostic or therapeutic catheters within the body for treatment and diagnosis of diseases. In particular, the present invention relates to reinforced balloon catheters and drug-eluting balloon catheters and corresponding methods for producing same.

Disorders are diagnosed by analyzing biological samples of ad libitum-fed and dietary-restricted individuals to generate frequency distribution patterns representative of molecular constituents of the samples, and comparing the patterns.

The present invention provides methods for identifying various biological states. Methods for diagnosis of diseases, in particular cardiovascular and brain diseases, are provided herein. One aspect of the invention is the analysis of lipoprotein complexes with summary survey scan mass spectrum for the analysis of biological states. Another aspect of the invention is the use of matrix assisted laser desorption ionization (MALDI) mass spectrometer to analysis lipoprotein complexes for the diagnosis of cardiovascular and brain diseases. Yet another aspect of the invention is a method of diagnosis of brain diseases by evaluating the characteristics of lipoprotein complexes.

A system and method of diagnosing diseases from biological data is disclosed. A system for automated disease diagnostics prediction can be generated using a database of clinical test data. The diagnostics prediction can also be used to develop screening tests to screen for one or more inapparent diseases. The prediction method can be implemented with Bayesian probability estimation techniques. The system and method permit clinical test data to be analyzed and mined for improved disease diagnosis.

Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.

The invention relates to an intelligent inquiry method and device, and belongs to the technical field of data processing. The method comprises the steps of detecting initial symptoms provided by a patient and determining and inquiring whether or not the patient has a first relevant symptom according to a Bayesian network; when it is detected that the patient has the first relevant symptom and it is judged that the diagnosis probability of a first candidate disease reaches a first threshold value, determining the first candidate disease as a diagnosis disease and making a feedback; when it is judged that the diagnosis probability of the first candidate disease does not reach the first threshold value, determining and inquiring whether or not the patient has a second relevant symptom of thefirst candidate disease according to the Bayesian network; when it is detected that the patient has the second relevant symptom and it is judged that the diagnosis probability of the first candidate disease reaches a second threshold value, determining the first candidate disease as a diagnosis disease and making a feedback. According to the intelligent inquiry method and device, on one hand, thecorresponding relationship between the disease and the diagnose is more comprehensive and flexible, and thus the diagnose result is more accurate; on the other hand, the interactive experience and effect of a user are optimized.

Disclosed herein are novel methods, assays and systems for determining a given state of a cell or a tissue by detecting the presence or absence of a short RNA molecule originating from (a) at least one or more exons of at least one or more protein-coding genes, or from (b) at least one or more segments of at least one or more non-coding transcripts, or from (c) both (a) and (b), in a biological sample from a subject. In some embodiments, the methods, assays and systems described herein can be used to identify an origin and/or a type of a cell or tissue, and/or distinguish a cell or tissue from another cell or tissue. In some embodiments, the methods, assays and systems described herein can also be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder in a subject.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

The invention relates to the field of biological chips, in particular to a protein chip for detecting a specific glycoprotein, antibody or antigen by surface plasmon resonance technology and a surface plasmon resonance principle-based detection method. The chip is provided with a metal film on a substrate; a connection layer is fixed on the surface of the metal film; agglutinin or other antigen or antibody is fixed on the connection layer; and the connection layer is prepared by activating a self-assembled monomolecular layer consisting of long-chain mercaptoethanol of which one end is provided with an active group and the other end reacts with the metal film through mercapto. The chip diagnoses diseases by the specific binding of the agglutinin and the specific glycoprotein and the binding of the specific antigen and antibody and provides a new way for disease diagnosis. The method is simple and practical, has low cost, simplifies operation steps, shortens detection time and is a novel method suitable for popularization.

The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

The invention relates to analysis methods for diagnosing diseases on human and animal samples. Said invention also relates to an evaluation method for diagnosing the individual stages of a disease in such a way that it is possible to display the progression thereof. Said invention also makes it possible to identify diseases in an early manner and to carry out therapeutic controls. The inventive method consists in carrying out actually known multivariable evaluation methods for classifying samples. Nevertheless, the invention is characterised in that no sample is allocated to a certain class, but it is classified in a data record based on the interpolation between different classes.

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention discloses a doctor online recommendation method and system. The method comprises the steps: obtaining basic attribute information and an illness state chief complaint text of a patient to whom a doctor is to be recommended; performing vectorization representation on the basic attributes and the illness state chief complaint text of the patient; obtaining a preliminarily recommended department according to vectorization representation of the illness state chief complaint text; extracting disease symptom entity words of the patient from a disease symptom entity word database according to the features of the disease condition chief complaint text of the patient; matching the disease symptom entity words of the patient with the skilled diagnosis disease description of each doctorof the preliminarily recommended department, and screening out matched doctors of a first type; according to the similarity between the vectorization representation of the basic attributes of the patient and the illness state chief complaint text and the vectorization representation of the basic attributes of the patient and the illness state chief complaint text and and historical patient scoresof each doctor in the first type of doctors, calculating a final recommendation score of each doctor; and outputting the information of the doctors with the highest score.

The invention discloses a methylated marker IL-2RG in a systemic lupus erythematosus (SLE) whole blood genome and application thereof. The sequence of the marker is shown as SEQ ID NO:1. The methylated marker IL-2RG in the SLE whole blood genome is applied to the preparation of a reagent for diagnosing SLE, in particular to a kit for diagnosing SLE. By detecting the methylation level of the methylated marker IL-2RG, a specific methylation locus with a great meaning and a remarkable difference is counted and taken as a basis for early diagnosis of SLE. By adopting the methylated marker, an accurate, cheap and quick clinical tool for early diagnosis of SLE, the disease activity, the curative effect and the prognostic evaluation is provided.